Gilead Sciences, Inc. (GILD)
Pre-Market:
| Previous Close | 65.42 |
| Open | 65.20 |
| Bid | 65.93 x 300 |
| Ask | 66.01 x 700 |
| Day's Range | 65.20 - 66.90 |
| 52 Week Range | 64.63 - 87.87 |
| Volume | |
| Avg. Volume | 7,429,945 |
| Market Cap | 82.225B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 183.17 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.08 (4.67%) |
| Ex-Dividend Date | Jun 14, 2024 |
| 1y Target Est | N/A |
- Business Wire
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
- Business Wire
Gilead Sciences Announces First Quarter 2024 Financial Results
FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.
- ACCESSWIRE
Gilead Sciences Publishes 2023 ESG Impact Report
NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's ...
